MedinCell receives €4 million in funding from Bpifrance and within the framework of the French Recovery Plan (Plan France Relance)

December 1, 2021

• €3 million loan for the development of a long-acting ivermectin-based drug designed to protect against Covid-19 and its variants for several weeks (mdc-TTG program)
• €1 million grant from the French Ministry of Industry’s call for project “Resilience”, which is part of the France Recovery Plan, for its new laboratory at the Jacou site, France

Bpifrance is a long-standing partner of our company”, said Jaime Arango, CFO of MedinCell. “It has already provided financial support for several of our projects, as it is doing today with our Covid-19 research program, which aims to develop a protective treatment against the virus and its variants. Bpifrance is also supporting the company’s overall growth by supporting the investments needed to expand and advance our portfolio, which will result in increased activity at our Jacou site.

We are delighted to renew our confidence in MedinCell and to support its growth through a €3 million loan, which will help finance its R&D work on high-potential technologies in the healthcare field” said Bpifrance.

> The company will provide an update on the development of its portfolio at the half-yearly results presentation on Wednesday, December 8, 2021

Session en français

Rendez-vous le lundi 14 novembre à 18h00 (CET) pour une vidéoconférence dédiée aux récentes avancées des produits de notre portfeuille clinique

English session

On Monday 14, November at 6.00 pm (CET) participate in our videoconference dedicated to the latest news regarding our clinical and regulatory products

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.


  • This field is for validation purposes and should be left unchanged.